Combination Therapy for Chronic Hepatitis B
Author Information
Author(s): Wang Zhao, Wu Xiao-Ling, Zeng Wei-Zheng, Xu Hui, Zhang Yong, Qin Jian-Ping, Jiang Ming-De
Primary Institution: Chengdu Military General Hospital
Hypothesis
Is adefovir plus lamivudine more effective than lamivudine alone for treating chronic hepatitis B patients with viral relapse?
Conclusion
Combination therapy with lamivudine and adefovir leads to better treatment outcomes for chronic hepatitis B patients compared to lamivudine alone.
Supporting Evidence
- 84% of patients on lamivudine plus adefovir achieved ALT normalization compared to 53.6% on lamivudine alone.
- 80% of patients on lamivudine plus adefovir had HBV DNA levels below 1000 copies/mL compared to 42.9% on lamivudine alone.
- 7 patients on lamivudine plus adefovir achieved HBeAg seroconversion, while none on lamivudine alone did.
Takeaway
Using two medicines together can help people with a liver infection feel better than just using one medicine.
Methodology
A prospective controlled study comparing the efficacy and safety of lamivudine plus adefovir versus lamivudine alone in 53 HBeAg-positive patients.
Limitations
The study had a limited sample size and short observation time.
Participant Demographics
53 HBeAg-positive patients, with 25 receiving lamivudine plus adefovir and 28 receiving lamivudine alone.
Statistical Information
P-Value
0.003
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website